The PNS Nurse Program: A Health Care Support Concept for Patients With Immune-Mediated Peripheral Nervous System Diseases.

Background

Immune-mediated peripheral nervous system (PNS) disorders pose diagnostic and therapeutic challenges, necessitating collaborative, patient-centered care. Limited access to specialized centers leads to delayed diagnosis and care, as seen during the COVID-19 pandemic. To address these challenges, accessible specialized care is crucial. On-site support plays a vital role in advising and assisting patients and caregivers, enabling multidisciplinary care for PNS diseases.

Recent Findings

The PNS Nurse Education Program tackles these complexities, using specialized nurses experienced in multiple sclerosis and Parkinson disease. Focusing on peripheral neuroimmunologic disorders, PNS nurses monitor disease severity, optimize communication, and provide therapeutic support in the recently started era of available immunotherapies. Collaboration with other healthcare sectors and support groups further enhances patient care.

Implications for Practice

Ultimately, the PNS Nurse Education Program aims to bridge the gap between complex treatments and limited specialized care, improving patient outcomes and relieving burdens on patients, caregivers, and healthcare systems.

Informations de copyright

Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Déclaration de conflit d'intérêts

M. Pawlitzki received honoraria for lecturing from Alexion, Argenx, Biogen, Bayer, Novartis, Hexal, Sanofi, and Merck. He received research funding from Biogen. M. Gasis reports no conflicts of interests. L. Masanneck receives honoraria for lecturing and travel expenses for attending meetings from Biogen, Merck, and Novartis. His research is funded by the German Multiple Sclerosis Society North Rhine-Westphalia (DMSG). S.G. Meuth receives honoraria for lecturing and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Healthcare, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS, and Teva. His research is funded by the German Ministry for Education and Research (BMBF), Deutschen Forschungsgesellschaft (DFG), Else Kröner Fresenius Foundation, German Academic Exchange Service, Hertie Foundation, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology, and by Almirall, Amicus Therapeutics Germany, Biogen Idec, Diamed, Fresenius Medical Care, Genzyme, Merck Healthcare, Novartis, ONO Pharma, Roche, and Teva. T. Ruck reports grants from German Ministry of Education, Science, Research, and Technology; grants and personal fees from Sanofi-Genzyme, Argenx, and Alexion Pharmaceuticals Inc.; personal fees from Argenx, Biogen, Roche, and Teva; and personal fees and nonfinancial support from Merck Serono. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.